Lexaria’s DehydraTECH-CBD Lowers Blood Pressure

Human Clinical Study HYPER-H21-1 evidences a rapid and sustained drop in blood pressure with DehydraTECH-CBD and excellent tolerability
Lexaria Bioscience

Lexaria Bioscience Corp. (Nasdaq:LEXX) (Nasdaq:LEXXW) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms is extremely pleased to issue partial results from human clinical study HYPER-H21-1 evaluating DehydraTECHTM-processed cannabidiol (“CBD”) for potential application against hypertension. Partial results related to blood pressure (“BP”) are being released today, while additional BP subset analyses and all other data analyses including pharmacokinetic (“PK”) evaluations and detailed blood chemistry work is in progress and will be released when complete. read more

Lexaria Completes Dosing in Human Clinical Study HYPER-H21-2

Additionally, second patent award received in Japan
Lexaria Bioscience

Lexaria Bioscience Corp. (NASDAQ:LEXX) (NASDAQ:LEXXW) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms is pleased to announce that dosing has been completed in its second human clinical study of 2021. read more

Lexaria Issues Progress Report on First Human Clinical Study of 2021, HYPER-H21-1

Dosing is complete in first of three human clinical studies hoped to validate Lexaria’s patented technology for hypertension relief – Study tested an advanced “DehydraTECH™ 2.0” CBD formulation – Second human clinical study, HYPER-H21-2, to commence immediately
Lexaria Bioscience

Lexaria Bioscience Corp. (Nasdaq:LEXX) (Nasdaq:LEXXW) (CSE:LXX) (CNSX:LXX.CN) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms, is pleased to report that treatment and dosing in its human clinical study (HYPER-H21-1) have been completed ahead of schedule. read more